Company Overview and News
Chevin Mandawala and Sagar Hiranand of MullenLowe Sri Lanka outshone their peers in the digital category at the Sri Lankan leg of Young Spikes 2016, recently. Their winning idea – Marco Knorrs it – highlighted their intimate understanding and use of digital platforms to increase the strength of Knorr and increase its usage. With this victory, the duo have won the honour of representing Sri Lanka at the Young Spikes Digital Competition to be held during the Spikes Asia Festival of Creativity in Singapore.
(PRESS RELEASE) – Amana Takaful Life Limited (ATLL), a fully-owned subsidiary of Amana Takaful PLC, rang the opening bell to commence trading and celebrate the listing ofits shares on the Diri Savi Board of the Colombo Stock Exchange (CSE) today.
Amana Takaful Life Limited (ATLL), a fully-owned subsidiary of Amana Takaful PLC, rang the opening bell to commence trading and celebrate the listing of its shares on the Diri Savi Board of the Colombo Stock Exchange (CSE) today.
Endorsing their presence and commitment to quality in all areas of operations, Amãna Takaful (ATL) PLC won two highly acclaimed awards in multiple subject areas, at the inaugural Sri Lanka insurance industry awards 2016.
ATLL first segregated Lankan Life Insurer to announce IPO post segregation of Insurance industry on 1st February 2015
June 28, 2016 (LBO) – Amana Takaful Life Limited (ATLL), a fully-owned subsidiary of Amana Takaful PLC, has announced an Initial Public Offering (IPO), via an offer for sale of 75 million rupees.
Amana Takaful Life Limited (ATLL), a fully-owned subsidiary of Amana Takaful PLC, has announced an Initial Public Offering (IPO), via an Offer for Sale of LKR 75 million, thereby becoming the first segregated life insurer in Sri Lanka to do so following the mandatory segregation of Life and General insurance companies on 1st February 2015.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...